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Abstract
Diurnal variations in blood pressure (BP) loss are closely associated with target organ damage and cardiovascular events. The
quantity of coronary artery calciﬁcation (CAC) correlates with the atherosclerotic plaque burden, and an increased quantity indicates a
substantially increased risk of cardiovascular events. This study investigated the nighttime diurnal variation in BP loss associated with
CAC in patients with chronic kidney disease (CKD).
Of the 1958 participants, we enrolled 722 participants with CKD without a history of acute coronary syndrome or symptomatic
coronary artery disease. CAC was measured with computed tomography. BP was measured using 24-hour ambulatory BP
monitoring. Central BP was measured using a SphygmoCor waveform analysis system.
Participants with CAC had signiﬁcantly higher 24-hour systolic, daytime systolic, and nighttime systolic ambulatory BP and central
systolic BP. The percentage of participants with dipping loss was signiﬁcantly higher among those with CAC. Multivariate logistic
regression analysis indicated that dipping loss and dipping ratio were independently associated with CAC after adjusting for
traditional and nontraditional cardiovascular risk factors and other BP parameters, including measurements of ofﬁce-measured BP
and central BP. The dipping status improved risk prediction for CAC after considering traditional risk factors and ofﬁce-measured BP,
using the net reclassiﬁcation improvement and integrated discrimination improvement.
Nighttime loss of diurnal variation in BP is an independent risk factor for CAC in CKD patients.
Abbreviations: ABPM = Ambulatory blood pressure monitoring, ACEis = Angiotensin-converting enzyme inhibitors, ARBs =
Angiotensin receptor blockers, BBs = Beta blockers, BP = Blood pressure, CAC = Coronary artery calciﬁcation, CAD = Coronary
artery disease, CCBs = Calcium channel blockers, CKD = Chronic kidney disease, CPP = Calcium-phosphate product, CVD =
Cardiovascular disease, DBP = Diastolic BP, eGFR = Estimated glomerular ﬁltration rate, HbA1C = Hemoglobin A1C, HDL = High-
density lipoprotein, IDI = Integrated discrimination improvement, LDL = Low-density lipoprotein, NRI = Net reclassiﬁcation
improvement, PP = Pulse pressure, SBP = Systolic BP, UACR = Urine albumin-to-creatinine ratio.
Keywords: blood pressure, chronic kidney disease, coronary calcium score, dipping
1. Introduction reported to increase early during the natural history of CKD and
has shortened the time to progression to dialysis therapy in largeCardiovascular disease (CVD) is a major cause of death in
chronic kidney disease (CKD) patients.[1–3] CVD risk has beenEditor: Jose Zacarías Parra Carrillo.
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Coronary artery calciﬁcation (CAC) measured using computed
tomography is a noninvasive method of assessing the burden of
coronary atherosclerosis. Patients with CKD have been shown to
have higher CAC scores and higher incidence rates for future
development of de novo CAC, even in the absence of baseline
CAC. Cross-sectional analyses have also reported a relationship
between lower estimated glomerular ﬁltration rate (eGFR) and
increased CAC.[6–8] Interestingly, the optimal cut-off score for
CAC that is used to predict obstructive coronary artery disease
(CAD) is higher for patients withmoderate CKD than for patients
without signiﬁcant CKD.[9]
Blood pressure (BP) control has an important role in CVD and
the progression of kidney failure in CKD patients.[10,11]
Hypertension may be involved in the atherogenic process, which
is considered amechanism of CAC.[12] Recently, not only high BP
but also diurnal variations in BP have been reported to be
associated with CVD events and stroke in CKD patients.[13–15]
Nocturnal nondipping, which is an abnormal elevation of
nocturnal BP compared with daytime BP, has been considered to
reﬂect the loss of diurnal BP variation. The prevalence of
nondipping is relatively high in patients with diabetes or reduced
renal function.[13,16,17] In a prospective cohort study, abnormal
diurnal variations in BP were associated with CAC in young,
[18]
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another cross-sectional study showed that BP dipping was not
signiﬁcantly associated with CAC score, although average BP
levels determined by 24-hour ambulatory BPmonitoring (ABPM)
showed an improved ability to predict the presence of CAC.[19]
The present study investigated whether nighttime dipping loss
was associated with CAC and whether this relationship was
maintained after adjustment for traditional or nontraditional
atherosclerosis risk factors and other parameters of BP for CKD
patients. In addition, this study attempted to elucidate the
predictive value of 24-hour BP measurements for CAC in CKD
patients.2. Methods
2.1. Participants
Participants in the Cardiovascular and Metabolic Disease
Etiology Research Center High-Risk Cohort [(CMERC-HI):
Individualized prevention strategy for high-risk patients in CVD:
prospective cohort studyNCT02003781; ClinicalTrial.gov] were
screened.[20] Of the 1958 participants who were enrolled into the
CMERC-HI cohort between November 2013 and May 2016,
participants with CKD, deﬁned as an increased urine albumin-to-
creatinine ratio (UACR) (≥17 for men and ≥25mg/g for women)
and eGFR ≥60mL/min/1.73m2 or eGFR <60mL/min/1.73m2,
were enrolled in this study. Participants with atrial ﬁbrillation or
those who underwent dialysis or kidney transplantation were
excluded (Fig. 1).[21,22]
A medical history assessment and physical examination were
performed to gather additional information, including sex,
hypertension, diabetes, use of anti-hypertensive agents [such as1,958 participants in the Cardiovascular and Me
Etiology Research Center High-Risk Cohort Stu
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Figure 1. Algorithm used to
2angiotensin receptor blockers (ARBs) or angiotensin-converting
enzyme inhibitors (ACEis), beta blockers [BBs], and calcium
channel blockers (CCBs)], statin use, BP, and body mass index
(kg/m2). Laboratory ﬁndings included hemoglobin, high-density
lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL)
cholesterol, calcium-phosphate product (CPP), fasting serum
glucose, uric acid, serum albumin, hemoglobin A1C (HbA1C),
eGFR, and UACR.[23,24] eGFR was calculated from serum
creatinine values by using the CKD Epidemiology Collaboration
(CKD-EPI) creatinine equation adjusted for age, sex, and race.[25]
This study was approved by the Institutional Review Board of
Severance Hospital, Yonsei University College of Medicine,
Seoul, Korea (4-2013-0581). The study was performed in
accordance with the ethical principles of the 1975 Declaration
of Helsinki. All patients provided informed consent.2.2. Blood pressure and hydration status measurement
Ofﬁce BP was measured using an oscillometric Omron HEM-
7080IC automatic BP device (IntelliSense; Omron, Kyoto,
Japan). Three consecutive seated BP readings were recorded at
intervals of 3 to 5minutes. Ofﬁce BP was calculated as the mean
of the 3 BP readings. Pulse pressure (PP) was obtained by the
difference between the systolic and diastolic pressure readings.
The 24-hour ABPM was performed using a Takeda TM-2430
instrument (A&D Medical, Tokyo, Japan), with readings taken
every 30minutes. Daytime and nighttime periods were deﬁned
according to information provided by the patient. The
ambulatory BP readings at 24hours, daytime, and nighttime
were averaged. Nighttime dipping was deﬁned as>10%decrease
in mean systolic BP (SBP) at night, and dipping status was
presented as dipping loss and dipping ratio. Loss of dipping wastabolic Disease 
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deﬁned as the ratio of the mean nighttime SBP to the mean
daytime SBP.[18] Higher systolic ABPM status was deﬁned as a
mean SBP ≥130mm Hg as measured using 24-hour ABPM.[26]
Central BP was measured using a SphygmoCor waveform
analysis system (AtCor Medical, Sydney, NSW, Australia) as
previously reported.[27,28]
2.3. Coronary artery calciﬁcation score measurement
Participants were scanned using 320-detector row computed
tomography (Aquillion ONE; Toshiba Medical Systems Corpo-
ration, Tokyo, Japan). A nonenhanced prospective electrocar-
diogram was performed to measure the CAC score with the
following parameters: rotation time, 275ms; slice collimation,
0.5mm; slice thickness, 3.0mm; tube voltage, 100kV; and
automatic tube current modulation (SURE Exposure 3D
standard; Toshiba Medical Systems Corporation, Otawara,
Japan). Images were analyzed in a core workstation by using
dedicated software (TeraRecon V. 4.4.11.82.3430.Beta; TeraR-
econ, Foster City, CA). The CAC score was measured using the
Agatston method.[29,30]
The total CAC score was the sum of all individual calciﬁed
lesions identiﬁed within the area of the coronary arteries. CAC
scores >100U indicated CAC.[22,31]2.4. Statistical analysis
All continuous variables are reported as the median (Q1–Q3)
based on the Shapiro–Wilk test, which indicated that data were
not normally distributed. Categorical data are expressed as a
number and percentage. The groups were statistically compared
using the x2 test and the Mann–Whitney U test, which is a
nonparametric statistical method. Univariate and multivariate
logistic regression analyses were used to determine the associa-
tion between CAC and dipping status by adjusting for the
inﬂuence of confounders. We quantiﬁed the improvement ofTable 1
Characteristics of all participants, classiﬁed by CAC.
All participants (n=722) Participants
Age, y 65.0 [56.0–71.0] 62.
Sex [male, n (%)] 316 (43.8)
Hypertension [yes, n (%)] 640 (88.6)
Diabetes [yes, n (%)] 334 (46.3)
ACEi or ARB use [yes, n (%)] 409 (56.6)
BB use [yes, n (%)] 225 (31.2)
CCB use [yes, n (%)] 314 (43.5)
Statin use [yes, n (%)] 351 (48.6)
BMI, kg/m2 25.1 [22.9–27.5] 25.
Hemoglobin, g/dL 13.0 [12.0–14.0] 13.
HDL-cholesterol, mg/dL 45.5 [38.0–54.0] 46.
LDL-cholesterol, mg/dL 90.0 [71.0–112.0] 94.
CPP 36.0 [27.0–36.0] 36.
Fasting glucose, mg/dL 104.0 [94.5–124.0] 101.
Uric acid, mg/dL 6.0 [5.0–7.0] 6.
Albumin, g/dL 4.0 [4.0–4.0] 4.
HbA1C, % 6.0 [6.0–7.0] 6.
eGFR, mL/min/1.73m2 56.4 [32.4–67.3] 56.
UACR, mg/g 120.0 [33.0–324.0] 129.
Data are expressed as number (%) or median [Q1-Q3].
ACEi= angiotensin-converting enzyme inhibitors, ARB= angiotensin II receptor blockers, BB= beta blocke
= calcium-phosphate product, eGFR = estimated glomerular ﬁltration rate, HbA1C = hemoglobin A1C, HD
3dipping status for CAC risk prediction with the net reclassiﬁca-
tion improvement (NRI) and integrated discrimination improve-
ment (IDI) indices.[32]P values <.05 were considered statistically
signiﬁcant. All analyses were conducted using SAS version 9.4
software (SAS Institute, Cary, NC) and R package version 3.0.1.3. Results
3.1. Participant characteristics
Baseline characteristics of the participants are summarized in
Table 1. The 722 CKD patients who were included had a median
age of 65.0 years. The median eGFR level was 56.4mL/min/1.73
m2 and the median UACR was 120mg/g. Clinical characteristics
and biochemical ﬁndings of patients without and with CAC are
also summarized in Table 1. Two-hundred ﬁfty patients
demonstrated high CAC scores (>100U). Age, male sex, diabetes
prevalence, BBorCCBuse, and statin usewere signiﬁcantly greater
for participants with CAC than for those without CAC, whereas
the use of ACEi or ARBwas greater for participants without CAC.
The prevalence of hypertension was similar between the 2 groups.
Participants with CAC had higher fasting glucose and HbA1C
levels and lower hemoglobin, LDL cholesterol, and HDL
cholesterol levels than those without CAC. CPP, eGFR, and
UACR values were not signiﬁcantly different (Table 1).
Table 2 summarizes the BP parameters of participants
classiﬁed according to CAC. Ofﬁce SBP, ofﬁce DBP, and PP
were signiﬁcantly higher for participants with CAC than for those
without CAC. Participants with CAC had signiﬁcantly higher 24-
hour systolic ABPM, daytime systolic ABPM, and nighttime
systolic and diastolic ABPM than participants without CAC.
Central SBP was also signiﬁcantly higher for participants with
CAC than for those without CAC [128.0 (112.0–141.0) vs 116.0
(107.0–129.0) mm Hg; P< .0001] (Table 2). The loss of dipping
percentage and dipping ratio were signiﬁcantly higher among
participants with CAC [56.0% vs 44.4%, P= .003; 0.92
(0.86–0.97) vs 0.90 (0.84–0.95), P= .001] (Fig. 2).without CAC (n=472) Participants with CAC (n=250) P
0 [52.0–69.0] 69.0 [62.0–73.0] <.001
187 (39.6) 129 (51.6) .002
418 (88.6) 222 (88.8) .923
169 (35.8) 165 (66.0) <.001
285 (60.4) 124 (49.6) .005
134 (28.4) 91 (36.4) .027
191 (40.5) 123 (49.2) .024
216 (45.8) 135 (54.0) .035
0 [22.8–27.6] 25.1 [23.3–27.2] .536
0 [12.0–14.0] 13.0 [11.0–14.0] .022
0 [39.0–56.0] 44.0 [36.0–51.0] <.001
0 [74.0–115.0] 83.0 [65.0–103.0] <.001
0 [27.0–36.0] 36.0 [30.0–40.0] .127
0 [93.0–115.0] 111.0 [97.0–134.0] <.001
0 [5.0–7.0] 6.0 [5.0–7.0] .358
0 [4.0–4.0] 4.0 [4.0–4.0] .569
0 [6.0–6.0] 6.0 [6.0–7.0] <.001
8 [32.6–67.3] 55.2 [32.2–67.3] .071
0 [32.0–352.0] 112.0 [39.0–271.0] .597
rs, BMI= body mass index, CAC= coronary artery calciﬁcation, CCB= calcium channel blockers, CPP
L = high-density lipoprotein, LDL = low-density lipoprotein, UACR = urine albumin-to-creatinine ratio.
Table 3
Univariate logistic regression analysis to determine the indepen-
dent factors affecting CAC.
Variables OR (95% CI) P
Male 1.62 (1.19–2.21) .002
Age 1.07 (1.05–1.09) <.001
Hypertension (yes) 1.02 (0.63–1.66) .923
Diabetes (yes) 3.48 (2.52–4.80) <.001
ACEi or ARB (yes) 0.65 (0.47–0.88) .006
BB use (yes) 1.44 (1.04–2.00) .027
CCB use (yes) 1.42 (1.05–1.94) .025
Statin use (yes) 1.39 (1.02–1.89) .035
BMI 1.02 (0.97–1.06) .444
Hemoglobin 0.91 (0.85–0.99) .024
HDL cholesterol 0.98 (0.96–0.99) <.001
CPP 1.02 (0.99–1.04) .188
Table 2
Blood pressure parameters of the participants, classiﬁed by CAC.
All participants (n=722) Participants without CAC (n=472) Participants with CAC (n=250) P
Ofﬁce SBP, mm Hg 128.3 [118.0–138.7] 126.3 [117.3–134.7] 132.3 [119.3–145.7] <.001
Ofﬁce DBP, mm Hg 74.9 [67.7–81.7] 76.3 [69.2–82.3] 72.3 [66.3–79.7] <.001
PP, mm Hg 52.3 [44.0–62.0] 49.3 [41.7–58.3] 58.0 [49.2–69.7] <.001
24-h systolic ABPM, mm Hg 129.0 [120.0–139.0] 127.0 [119.0–137.0] 133.0 [125.0–143.0] <.001
24-h diastolic ABPM, mm Hg 77.0 [72.0–82.0] 77.0 [71.0–81.0] 76.0 [72.0–82.0] .598
Daytime systolic ABPM, mm Hg 133.5 [125.0–145.0] 132.0 [123.0–142.0] 138.0 [127.0–148.0] <.001
Daytime diastolic ABPM, mm Hg 80.0 [74.0–85.0] 80.0 [74.0–85.0] 80.0 [75.0–85.0] .916
Nighttime systolic ABPM, mm Hg 120.0 [110.0–131.0] 117.0 [108.0–128.0] 125.0 [117.0–136.0] <.001
Nighttime diastolic ABPM, mm Hg 71.0 [66.0–77.0] 70.0 [65.0–76.0] 72.0 [66.0–77.0] .046
Higher ABPM 347 (48.1) 199 (42.2) 148 (59.2) <.001
Central SBP, mm Hg 119.0 [108.0–133.0] 116.0 [107.0–129.0] 128.0 [112.0–141.0] <.001
Central DBP, mm Hg 74.0 [68.0–81.0] 74.0 [68.0–80.0] 74.0 [68.0–82.0] .853
Data are expressed as number (%) or median [Q1-Q3].
ABPM = ambulatory blood pressure monitoring, CAC = coronary artery calciﬁcation, DBP = diastolic blood pressure, PP = pulse pressure, SBP = systolic blood pressure.
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with cardiovascular risk variables and blood pressure
parameters
Univariate logistic regression analysis to examine the association
of individual study covariates with CAC identiﬁed the following
risk factors that were included in multivariate models: cardio-
vascular conventional risk factors, including sex, age, diabetes,
hypertension, and HDL cholesterol; medications, such as use of
ACEi or ARB, BB, CCB, and statins; laboratory parameters, such
as hemoglobin, CPP, glucose, uric acid, albumin, HbA1C, eGFR,
and UACR; BP parameters, including ofﬁce SBP, higher ABPM,
daytime systolic ABPM, and central SBP; dipping loss; and
dipping ratio. Male sex, older age, diabetes, lower HDL
cholesterol and hemoglobin, and higher glucose and HbA1C
were signiﬁcant risk factors affecting CAC. In addition, higher
ofﬁce SBP, higher PP, higher systolic ABPM, higher daytime
systolic ABPM, and higher central SBP affected CAC. Loss of
dipping and dipping ratio were also signiﬁcant risk factors
affecting CAC [odds ratio (OR), 1.60; conﬁdence interval (CI),
1.17–2.18]; P= .003; OR, 20.00; CI, 3.10–129.00; P= .002]
(Table 3).
CAC was used as a dependent variable for multivariate logistic
regression analysis, and dipping status was entered as an
independent variable. We adjusted for traditional cardiovascularFigure 2. Mean dipping ratio values and percentages of loss of dipping
according to coronary artery calciﬁcation (CAC) status.
4risk factors (including age, sex, diabetes, hypertension, and HDL
cholesterol), laboratory parameters (such as hemoglobin, CPP,
and HbA1C), medications (including anti-hypertensives and
statins), and BP parameters (such as ofﬁce SBP, PP, higher ABPM,
daytime systolic ABPM, and central SBP) to investigate the effects
of dipping on CAC. Dipping loss and higher dipping ratio were
signiﬁcantly associated with higher CAC scores after adjustment
for traditional risk factors (loss of dipping: OR, 1.70; CI,Glucose 1.01 (1.00–1.01) <.001
Uric acid 1.04 (0.96–1.14) .333
Albumin 0.86 (0.57–1.29) .467
HbA1C 1.51 (1.29–1.76) <.001
eGFR 1.00 (0.99–1.00) .215
UACR 1.00 (1.00–1.00) .314
Ofﬁce SBP 1.03 (1.02–1.04) <.001
PP 1.05 (1.04–1.06) <.001
24-h systolic ABPM 1.04 (1.02–1.05) <.001
Daytime systolic ABPM 1.03 (1.02–1.04) <.001
Higher ABPM 1.99 (1.46–2.72) <.001
Central SBP 1.03 (1.02–1.03) <.001
Loss of dipping 1.60 (1.17–2.18) .003
Dipping ratio 20.00 (3.10–129.00) .002
ABPM = ambulatory blood pressure monitoring, ACEi = angiotensin-converting enzyme inhibitors,
ARB= angiotensin II receptor blockers, BB= beta blockers, BMI = body mass index, CAC = coronary
artery calciﬁcation, CCB = calcium channel blockers, CI = conﬁdence interval, CPP = calcium-
phosphate product, eGFR = estimated glomerular ﬁltration rate, HbA1C = hemoglobin A1C, HDL =
high-density lipoprotein, OR = odds ratio, PP = pulse pressure, SBP = systolic blood pressure, UACR
= urine albumin-to-creatinine ratio.
[36]
Table 4
Sequential multivariate logistic regression analysis according to dipping status.
Loss of dipping Dipping ratio
Variables OR (95% CI) P OR (95% CI) P
Adjusted by traditional risk factors 1.70 (1.19–2.43) .004 23.12 (2.65–201.49) .004
Adjusted by traditional risk factors + labs 1.72 (1.17–2.52) .006 13.66 (1.38–134.99) .025
Adjusted by traditional risk factors + meds 1.64 (1.14–2.37) .008 19.14 (2.10–174.75) .009
Adjusted by traditional risk factors + eGFR + UACR 1.50 (1.02–2.20) .040 12.537 (1.25–126.27) .032
Adjusted by traditional risk factors + Ofﬁce SBP 1.72 (1.19–2.47) .004 24.97 (2.78–224.24) .004
Adjusted by traditional risk factors + PP 1.69 (1.17–2.43) .005 22.13 (2.45–199.7) .006
Adjusted by traditional risk factors + Higher ABPM 1.70 (1.18–2.44) .004 19.43 (2.20–171.50) .008
Adjusted by traditional risk factors + Daytime systolic ABPM 1.91 (1.32–2.77) .001 40.61 (4.40–374.54) .001
Adjusted by traditional risk factors + Central SBP 1.60 (1.08–2.37) .019 18.12 (1.65–198.60) .018
Traditional risk factors: male sex, age, diabetes, hypertension, HDL cholesterol. Labs: hemoglobin, HbA1C, and CPP. Meds: ACEi or ARB, CCB, BB, and statin use.
ABPM = ambulatory blood pressure monitoring, ACEi = angiotensin-converting enzyme inhibitors, ARB = angiotensin II receptor blockers, BB = beta blockers, CCB = calcium channel blockers, CI = conﬁdence
interval, CPP = calcium-phosphate product, eGFR = estimated glomerular ﬁltration rate, HbA1C = hemoglobin A1C, HDL = high-density lipoprotein, OR = odds ratio, PP = pulse pressure, SBP = systolic blood
pressure, UACR = urine albumin-to-creatinine ratio.
Choi et al. Medicine (2017) 96:26 www.md-journal.com1.19–2.43; P= .004; dipping ratio: OR, 23.12; CI, 2.65–201.49;
P= .004). In addition, the multivariate logistic regression analysis
revealed that dipping loss and higher dipping ratio were
independently correlated with CAC after sequential adjustment
for traditional risk factors together with nontraditional risk
factors, laboratory parameters, including hemoglobin, CPP, and
HbA1C, medications such as stains and anti-hypertensives,
eGFR, and UACR. Loss of dipping and higher dipping ratio were
also independently associated with CAC after sequential
adjustment for traditional risk factors and any BP parameters
such as ofﬁce SBP, PP, higher ABPM, daytime systolic ABPM,
and central SBP (Table 4).
To evaluate the improvement of risk prediction with the
addition of dipping loss for CAC, we determined the NRI and IDI
indices. Loss of dipping provided improved risk prediction for
CAC: NRI was 0.113 (P= .001) and IDI was 0.012 (P= .006)
after accounting for traditional risk factors and ofﬁce SBP. The
dipping ratio also improved the risk prediction for CAC: NRI
was 0.088 (P= .004) and IDI was 0.012 (P= .006) after
accounting for traditional risk factors and ofﬁce SBP.4. Discussion
Early diagnosis or prevention of CVD is important for CKD
patients because they face markedly increased CVD morbidity
and mortality rates that cannot be fully explained by traditional
risk factors alone.[1,2] However, imaging modalities to identify
CAD are limited due to underestimation of CVD risk, and they do
not account for changes in left ventricular structure and
function[5] or contraindication of radiocontrast agents because
of nephrotoxicity.[33] In this regard, the CAC score is useful for
the early detection of CAD, and national guidelines primarily
recommended it for risk stratiﬁcation.[34,35]
The present study demonstrated that dipping status (such as
dipping loss and dipping ratio) is an independent risk factor for
CAC in CKD. To our knowledge, this study is the ﬁrst to
investigate the association between the diurnal variation in BP
and CAC in patients with CKD. We found that dipping status
was an independent risk factor for CAC in CKD patients, and
that CKD patients had signiﬁcantly higher CAC scores after
adjusting for traditional and nontraditional CVD risk factors or
BP parameters, including ofﬁce-measured BP, PP, 24-hour
ABPM, and central BP.
BP control has been a major target of treatment in CKD
patients because they are more susceptible to renal failure and5target organ damage with elevated BP. Although diurnal BP
variation has been reported to play an important role in CVD and
target organ damage, the management of BP in CKD patients is
usually based on BP measurements in a clinical setting due to its
simplicity.[13–15] The present study elucidated the association
between higher CAC and dipping status after adjustment for
other BP parameters, including ofﬁce-measured BP and central
BP measured using a SphygmoCor waveform analysis system.
Our data suggested that CKD patients who had loss of diurnal
variation in BP during 24-hour ABPM should be closely
monitored for the presence of CAC, even if they have optimal
ofﬁce-measured BP results. This study also determined that the
dipping status improved risk prediction for CAC using NRI and
IDI after accounting for traditional risk factors and ofﬁce-
measured BP. Central hemodynamic and arterial stiffness have
been reported to be associated with CVD in advanced CKD and
end-stage renal disease.[3,37–40] In addition, central SBP and PP
may predict CVD events and end-organ damage more accurately
than brachial BP.[3,41,42] In our data, central SBPwas signiﬁcantly
higher for CKD patients with CAC, and increased central SBP
together with other BP parameters was signiﬁcantly associated
with higher CAC in the univariate regression analysis. After
adjustment for central SBP and traditional risk factors in the
multivariate regression analysis, dipping loss and higher dipping
ratio were signiﬁcantly associated with CAC. However, no
signiﬁcant association was shown between the loss of diurnal
variation and CAC for the participants without CKD in this
cohort data (data not shown). Therefore, the association between
CAC and loss of diurnal variation in BP may be evident only for
participants with CKD.
The amount of CAC correlates closely with the amount of
atherosclerosis, and this forms the basis for the use of scoring to
improve risk prediction beyond clinical variables in the general
population.[43] The extent of CAC is directly proportional to
increased cardiovascular event rates, and CAC scores of 100 (or
75th percentile) indicate high CVD risk. A meta-analysis by
Pletcher et al[44] showed that with a CAC score between 1 and
100, the relative risk of major adverse cardiovascular events
doubles (hazard ratio, 2.1), but the risk is 3- to 17-fold higher for
an Agatston score above this range. However, CAC is more
common in patients with CKD, and atherosclerotic plaques have
higher calcium content than those in patients without CKD. The
mean Agatston scores were shown to be higher than those for
controls: 175U higher for patients with stage 2 CKD and 693U
higher for patients with stage 3 CKD.[45] A Chronic Renal
[3] Goupil R, Dupuis D, Agharazii M, et al. Central blood pressures in early
Choi et al. Medicine (2017) 96:26 MedicineInsufﬁciency Cohort study investigator demonstrated that the
severity of CKD and CAC scores had a graded relationship.[6] A
single-center study showed that the highest CAC score quartile
was associated with a 2.5-fold increase in all-cause mortality
compared with the lowest quartile for patients with proteinuria
and diabetes with mild to moderate stages of CKD.[5,45]
Although the mechanism underlying the loss of diurnal
variation is unclear, it has been shown to be a consequence of
autonomic dysfunction, volume overload, and abnormal sodium
processing in CKD.[13,17,46–48] Anemia and disturbances of
calcium-phosphate metabolism, which are important clinical
indicators of the severity of CKD and are closely related to kidney
failure, were also correlated with the loss of diurnal variation.[48]
Our data revealed that participants with CAC had lower
hemoglobin levels and comparable CPP levels than participants
without CAC. However, hemoglobin and CPP did not show any
correlation with loss of dipping (data not shown). Loss of dipping
and higher dipping ratio were independent risk factors for CAC
inCKDpatients after adjusting for covariates such as hemoglobin
and CPP in this study.
One strength of this study was its analysis of many forms of BP
measurement, including ofﬁce BP, PP, 24-hour ABPM, and
central BP, which have recently been applied in clinical settings.
Moreover, the diurnal BP variation loss was shown to be
associated with CAC at all CKD stages in the present study. We
enrolled patients with mild CKD (stage 1 or 2), deﬁned as the
presence of increased urine albumin excretion and eGFR≥60mL/
min, and moderate to advanced CKD (stages 3–5), deﬁned as
eGFR <60mL/min. Our data indicated that LDL cholesterol,
which has been recognized as a CVD risk factor, was signiﬁcantly
lower and that statin use to prevent CVD was higher in patients
with CAC. These ﬁndings implied that patients with CKD should
be monitored with 24-hour ABPM for diurnal BP variation loss,
even if they have already received treatment and have been
monitored carefully.
This study has several limitations. First, our observations were
cross-sectional, and we used a small sample size; therefore, the
precise relationship between dipping and CAC remains unclear.
Prospective studies should be performed to determine whether
dipping loss can predict the progression of CAC in CKD. Second,
urinary sodium excretion levels were not obtained; therefore, we
could not determine whether the loss of dipping was induced by
impaired renal sodium excretion. Finally, diagnostic coronary
angiography could not be checked to conﬁrm the relationship
between the loss of diurnal variation inBPand the presence ofCAC
due to nephrotoxicity related to radiocontrast use inCKDpatients.
In conclusion, nighttime loss of diurnal variation in BP was
signiﬁcantly correlated with CAC and was an independent risk
factor for high CAC scores in CKD patients. Patients who do not
demonstrate dipping during 24-hour ABPM should be monitored
carefully for the development of CAC. Measurement of 24-hour
ABPM may predict CAC in CKD patients.
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